Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Boehringer Ingelheim
Medtronic
Teva
QuintilesIMS
Queensland Health

Generated: June 25, 2019

DrugPatentWatch Database Preview

Details for Patent: 5,559,111

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 5,559,111 protect, and when does it expire?

Patent 5,559,111 protects TEKTURNA and TEKTURNA HCT and is included in two NDAs.

Protection for TEKTURNA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-six patent family members in twenty-six countries.

Summary for Patent: 5,559,111
Title: .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides
Abstract:.delta.-Amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides of formula I ##STR1## and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive medicinal active ingredients.
Inventor(s): G oschke; Richard (Bottmingen, CH), Maibaum; J urgen K. (Weil-Haltingen, DE), Schilling; Walter (Himmelried, CH), Stutz; Stefan (Basel, CH), Rigollier; Pascal (Sierentz, FR), Yamaguchi; Yasuchika (Basel, CH), Cohen; Nissim C. (Village-Neuf, FR), Herold; Peter (Arlesheim, CH)
Assignee: Ciba-Geigy Corporation (Tarrytown, NY)
Application Number:08/416,242
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 5,559,111
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 5,559,111

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Noden Pharma TEKTURNA aliskiren hemifumarate TABLET;ORAL 021985-001 Mar 5, 2007 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Noden Pharma TEKTURNA aliskiren hemifumarate TABLET;ORAL 021985-002 Mar 5, 2007 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Noden Pharma TEKTURNA HCT aliskiren hemifumarate; hydrochlorothiazide TABLET;ORAL 022107-001 Jan 18, 2008 RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,559,111

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Switzerland1169/94Apr 18, 1994

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Harvard Business School
Cipla
Covington
Merck
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.